Shandong Xinqi Pharmaceutical

Shandong Xinqi Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Jinan, China, focused on the discovery and development of innovative small molecule therapeutics. The company's primary research focus is on oncology, where it aims to develop high-potency, selective treatments for various cancers. Its lead candidate, XQ-101, is a novel small molecule currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Shandong Xinqi utilizes its internal R&D capabilities to advance a pipeline of targeted therapies, positioning itself as an emerging player in the Chinese biotechnology sector. The company is dedicated to transforming scientific discoveries into effective clinical solutions for patients with unmet medical needs.